この製品に関するご意見・ご照会・お問合せはこちら

 How do Mu (B.1.621) & C.1.2 variants affect the war against SARS-CoV-2?

In August 2021, the new SARS-CoV-2 VOI variant Mu (PANGO lineage: B.1.621) sparked a wave of attention for its potential risk as a highly transmissible and immune-resistant strain. Since its first identification in January 2021 in Columbia, the variant has been responsible for most COVID-19 cases circulating in the country and its neighbors.

Simultaneously, on the other side of the globe, a C.1.2 strain with an unprecedented set of complicated mutations on the spike protein emerged in South Africa.

In response to the challenges of the emerging variants, ACROBiosystems has rapidly developed the spike protein mutants of Mu (B.1.621) and C.1.2, including Spike RBD, spike NTD and full-length spike trimer with high purity and good bioactivity

Product lists

Assay Data

• The purity of Cat. No. SPN-C52Ha is greater than 90% with the verification of SDS-PAGE and MALS. 

Immobilized SARS-CoV-2 Spike Trimer, His Tag (Cat. No. SPN-C52Ha) at 1 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL (QC tested). It can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.1-2 ng/mL (Routinely tested).